Skip to content
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact
Menu
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
Menu
  • Science
    • Barriers to Treatment in the Liver
    • Barriers to Treatment in the Pancreas
    • Overcoming Immunosuppression
    • Overcoming Intratumoral Pressure
    • Publications & Presentations
  • Platform
    • Drug Delivery Technology
  • Pipeline
    • Candidate SD-101
  • Clinical Trials
  • For Patients
  • About
  • News & Events
    • Press & Media
  • Culture
    • Careers
  • Partnering
  • Investors
  • Contact

Archives: Resources

Pancreatic Retrograde Venous Infusion (PRVI) Significantly Enhances Delivery of NearIR Labelled SD-101 TLR9 Agonist to Targeted Regions of the Porcine Pancreas.

…

Pressure-enabled intravascular delivery of SD-101 into the liver with systemic or subcutaneous checkpoint inhibitor for control of liver metastases in a murine model

…

Enhanced Delivery of a TLR9 Type C Agonist SD-101 to Liver Tumors in the Oncopig using Pressure Enabled Drug Delivery (PEDD) Versus a Standard Endhole Catheter

…

Pressure-Enabled Drug Delivery (PEDDTM) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model

…

Regional Infusion of a Class C TLR9 Agonist Enhances Liver Tumor Microenvironment Reprogramming and MDSC Reduction to Improve Responsiveness to Systemic Checkpoint Inhibition

…

Abstract No. 158628: PERIO-01: Enabling Tumor Microenvironment Reprogramming by a TLR9 Agonist Using Pressure-Enabled Drug Delivery™ (PEDD™) to Address Intrahepatic Immunosuppression and Drug Delivery Barriers

…

Antireflux Catheter Improves Tumor Targeting in Liver Radioembolization with Resin Microspheres

…

Abstract No. 1793: Regional Administration of Class C CpG Oligodeoxynucleotides Results in Superior Intrahepatic TLR9 Activation and Immunomodulation Compared to Systemic Infusion

…

HITM-SURE: Hepatic Immunotherapy for Metastases Phase Ib Anti-CEA CAR-T Study Utilizing Pressure Enabled Drug Delivery

…

Abstract No. 9534: Phase 1b/2, Open Label, Multicenter, Study of the Combination of SD-101 and Pembrolizumab in Patients with Advanced Melanoma Who Are Naïve to Anti-PD-1/L1 Therapy (SYNERGY-001/KEYNOTE-184, NCT02521870)

…
← older
© 2023 TriSalus Life Sciences, Inc. All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use
Linkedin Twitter
Linkedin Twitter
© 2023 TriSalus Life Sciences, Inc.
All rights reserved
  • Privacy Policy
  • Compliance
  • Terms of Use

IMPORTANT NOTICE

You are now leaving the Trisalus life Sciences corporate website.

We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from TriSalus’ standards.

Third Party Sites

TriSalus assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site’s endorsement of TriSalus or this website.

Thank you for visiting our site.

YES
CANCEL